Alerus Financial NA Has $7.84 Million Position in Johnson & Johnson (NYSE:JNJ)

Alerus Financial NA lifted its position in Johnson & Johnson (NYSE:JNJ) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 54,185 shares of the company’s stock after purchasing an additional 1,058 shares during the period. Alerus Financial NA’s holdings in Johnson & Johnson were worth $7,836,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $4,390,037,000. Raymond James Financial Inc. acquired a new position in Johnson & Johnson in the 4th quarter worth $1,339,878,000. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after purchasing an additional 2,356,359 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after buying an additional 1,729,281 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.9 %

Shares of JNJ opened at $163.22 on Friday. The stock has a market capitalization of $393.33 billion, a PE ratio of 24.54, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm’s 50 day moving average is $158.35 and its 200-day moving average is $156.23.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analysts Set New Price Targets

Several research firms have commented on JNJ. Bank of America boosted their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Barclays lifted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Citigroup reduced their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.